BeyondSpring CEO On Plinabulin's Dual Regulatory Pathway For US and China

 
• By Sten Stovall

BeyondSpring’s lead clinical asset, plinabulin, is currently in late-stage global registrational studies for the prevention of chemotherapy-induced neutropenia and treatment of lung cancer, with read-outs expected soon.  CEO Lan Huang discussed coming catalysts and their potential with Scrip.

Chemotherapy
A Key Coming Catalyst For Plinabulin Is In Treating chemotherapy-induced neutropenia • Source: Shutterstock

More from Business

More from Scrip